Pliant Therapeutics (PLRX) Cash from Operations (2019 - 2026)
Pliant Therapeutics (PLRX) reported Cash from Operations of 19229000.0 for Q1 2026, up 60.65% year-over-year from 11969653.83 in Q1 2025, and down 8.1% quarter-over-quarter from 17788000.0 in Q4 2025.
Pliant Therapeutics (PLRX) Cash from Operations (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has 8 years of Cash from Operations data on file, last reported at 19229000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 19229000.0, up 60.65% year-over-year; the trailing twelve-month figure through Mar 2026 was 98701000.0 (up 43.31% YoY), and the FY2025 annual result was 128336000.0, up 17.47% from the prior year.
- Cash from Operations retreated to 19229000.0 in Q1 2026 per PLRX's latest filing, from 17788000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 17788000.0 in Q4 2025 and troughed at 48864000.0 in Q1 2025.
- A 5-year average of 30238823.53 and a median of 30271000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2025: Cash from Operations slumped 95.83% in 2023, then soared 62.68% in 2025.
- A 5-year view of Cash from Operations shows it stood at 31239000.0 in 2022, then grew by 19.65% to 25102000.0 in 2023, then plunged by 89.87% to 47662000.0 in 2024, then soared by 62.68% to 17788000.0 in 2025, then dropped by 8.1% to 19229000.0 in 2026.
- Business Quant data shows PLRX's Cash from Operations at 19229000.0 in Q1 2026, 17788000.0 in Q4 2025, and 21081000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Pliant Therapeutics | 74.16 Mn | 74.16 Mn | - | -19.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.23 Mn |
| Mar 31, 2026 | -19.23 Mn |
| Dec 31, 2025 | -17.79 Mn |
| Dec 31, 2025 | -17.79 Mn |
| Sep 30, 2025 | -21.08 Mn |
| Sep 30, 2025 | -21.08 Mn |
| Jun 30, 2025 | -40.60 Mn |
| Jun 30, 2025 | -40.60 Mn |
| Mar 31, 2025 | -48.86 Mn |
| Mar 31, 2025 | -48.86 Mn |
| Dec 31, 2024 | -47.66 Mn |
| Dec 31, 2024 | -47.66 Mn |
| Sep 30, 2024 | -32.27 Mn |
| Sep 30, 2024 | -32.27 Mn |
| Jun 30, 2024 | -45.30 Mn |
| Jun 30, 2024 | -45.30 Mn |
| Mar 31, 2024 | -30.27 Mn |
| Mar 31, 2024 | -30.27 Mn |
| Dec 31, 2023 | -25.10 Mn |
| Dec 31, 2023 | -25.10 Mn |